Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324132617> ?p ?o ?g. }
- W4324132617 endingPage "1928" @default.
- W4324132617 startingPage "1916" @default.
- W4324132617 abstract "Radiopharmaceutical therapy is changing the standard of care in prostate cancer and other malignancies. We previously reported high CD46 expression in prostate cancer and developed an antibody-drug conjugate and immunoPET agent based on the YS5 antibody, which targets a tumor-selective CD46 epitope. Here, we present the preparation, preclinical efficacy, and toxicity evaluation of [225Ac]DOTA-YS5, a radioimmunotherapy agent based on the YS5 antibody.[225Ac]DOTA-YS5 was developed, and its therapeutic efficiency was tested on cell-derived (22Rv1, DU145), and patient-derived (LTL-545, LTL484) prostate cancer xenograft models. Biodistribution studies were carried out on 22Rv1 tumor xenograft models to confirm the targeting efficacy. Toxicity analysis of the [225Ac]DOTA-YS5 was carried out on nu/nu mice to study short-term (acute) and long-term (chronic) toxicity.Biodistribution study shows that [225Ac]DOTA-YS5 agent delivers high levels of radiation to the tumor tissue (11.64% ± 1.37%ID/g, 28.58% ± 10.88%ID/g, 29.35% ± 7.76%ID/g, and 31.78% ± 5.89%ID/g at 24, 96, 168, and 408 hours, respectively), compared with the healthy organs. [225Ac]DOTA-YS5 suppressed tumor size and prolonged survival in cell line-derived and patient-derived xenograft models. Toxicity analysis revealed that the 0.5 μCi activity levels showed toxicity to the kidneys, likely due to redistribution of daughter isotope 213Bi.[225Ac]DOTA-YS5 suppressed the growth of cell-derived and patient-derived xenografts, including prostate-specific membrane antigen-positive and prostate-specific membrane antigen-deficient models. Overall, this preclinical study confirms that [225Ac]DOTA-YS5 is a highly effective treatment and suggests feasibility for clinical translation of CD46-targeted radioligand therapy in prostate cancer." @default.
- W4324132617 created "2023-03-15" @default.
- W4324132617 creator A5002133501 @default.
- W4324132617 creator A5005387472 @default.
- W4324132617 creator A5010028846 @default.
- W4324132617 creator A5014357212 @default.
- W4324132617 creator A5015860537 @default.
- W4324132617 creator A5016332122 @default.
- W4324132617 creator A5019176693 @default.
- W4324132617 creator A5026285477 @default.
- W4324132617 creator A5028484752 @default.
- W4324132617 creator A5031713266 @default.
- W4324132617 creator A5033427647 @default.
- W4324132617 creator A5035923646 @default.
- W4324132617 creator A5039268687 @default.
- W4324132617 creator A5047250521 @default.
- W4324132617 creator A5049214744 @default.
- W4324132617 creator A5059356678 @default.
- W4324132617 creator A5068978500 @default.
- W4324132617 creator A5070724003 @default.
- W4324132617 creator A5074856469 @default.
- W4324132617 creator A5078648367 @default.
- W4324132617 creator A5081123075 @default.
- W4324132617 creator A5081788616 @default.
- W4324132617 creator A5087824476 @default.
- W4324132617 creator A5037532225 @default.
- W4324132617 date "2023-03-14" @default.
- W4324132617 modified "2023-10-18" @default.
- W4324132617 title "Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy" @default.
- W4324132617 cites W1884159022 @default.
- W4324132617 cites W1987853842 @default.
- W4324132617 cites W2070327519 @default.
- W4324132617 cites W2086163153 @default.
- W4324132617 cites W2099912528 @default.
- W4324132617 cites W2106543661 @default.
- W4324132617 cites W2115940435 @default.
- W4324132617 cites W2135368140 @default.
- W4324132617 cites W2141454098 @default.
- W4324132617 cites W2151732765 @default.
- W4324132617 cites W2523030593 @default.
- W4324132617 cites W2589224115 @default.
- W4324132617 cites W2767791453 @default.
- W4324132617 cites W2784080506 @default.
- W4324132617 cites W2791792477 @default.
- W4324132617 cites W2793652009 @default.
- W4324132617 cites W2801407049 @default.
- W4324132617 cites W2802125673 @default.
- W4324132617 cites W2808022995 @default.
- W4324132617 cites W2841858285 @default.
- W4324132617 cites W2892222776 @default.
- W4324132617 cites W2895961520 @default.
- W4324132617 cites W2896060946 @default.
- W4324132617 cites W2943293744 @default.
- W4324132617 cites W2967856517 @default.
- W4324132617 cites W2990493095 @default.
- W4324132617 cites W3005799109 @default.
- W4324132617 cites W3029012726 @default.
- W4324132617 cites W3032223428 @default.
- W4324132617 cites W3108377814 @default.
- W4324132617 cites W3112621369 @default.
- W4324132617 cites W3136990937 @default.
- W4324132617 cites W3176208875 @default.
- W4324132617 cites W4206841660 @default.
- W4324132617 cites W4206972486 @default.
- W4324132617 cites W4281752578 @default.
- W4324132617 cites W4282008339 @default.
- W4324132617 cites W4282937381 @default.
- W4324132617 cites W4283577156 @default.
- W4324132617 cites W4323971746 @default.
- W4324132617 cites W4376849722 @default.
- W4324132617 doi "https://doi.org/10.1158/1078-0432.ccr-22-3291" @default.
- W4324132617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36917693" @default.
- W4324132617 hasPublicationYear "2023" @default.
- W4324132617 type Work @default.
- W4324132617 citedByCount "5" @default.
- W4324132617 countsByYear W43241326172023 @default.
- W4324132617 crossrefType "journal-article" @default.
- W4324132617 hasAuthorship W4324132617A5002133501 @default.
- W4324132617 hasAuthorship W4324132617A5005387472 @default.
- W4324132617 hasAuthorship W4324132617A5010028846 @default.
- W4324132617 hasAuthorship W4324132617A5014357212 @default.
- W4324132617 hasAuthorship W4324132617A5015860537 @default.
- W4324132617 hasAuthorship W4324132617A5016332122 @default.
- W4324132617 hasAuthorship W4324132617A5019176693 @default.
- W4324132617 hasAuthorship W4324132617A5026285477 @default.
- W4324132617 hasAuthorship W4324132617A5028484752 @default.
- W4324132617 hasAuthorship W4324132617A5031713266 @default.
- W4324132617 hasAuthorship W4324132617A5033427647 @default.
- W4324132617 hasAuthorship W4324132617A5035923646 @default.
- W4324132617 hasAuthorship W4324132617A5037532225 @default.
- W4324132617 hasAuthorship W4324132617A5039268687 @default.
- W4324132617 hasAuthorship W4324132617A5047250521 @default.
- W4324132617 hasAuthorship W4324132617A5049214744 @default.
- W4324132617 hasAuthorship W4324132617A5059356678 @default.
- W4324132617 hasAuthorship W4324132617A5068978500 @default.
- W4324132617 hasAuthorship W4324132617A5070724003 @default.
- W4324132617 hasAuthorship W4324132617A5074856469 @default.
- W4324132617 hasAuthorship W4324132617A5078648367 @default.